Selecta Biosciences, Inc. SELB announced that the FDA has placed a clinical hold on its phase I/II study, which is evaluating its pipeline candidate SEL-302 for the treatment of patients with ...
GeekWire chronicles the Pacific Northwest startup scene. Sign up for our weekly startup newsletter, and check out the GeekWire funding tracker and VC directory. by Charlotte Schubert on Sep 9, 2021 at ...
WATERTOWN, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic ...
Selecta Biosciences Inc SELB provided an update on its ongoing strategic initiative to maximize stockholder value related to its economic interests in SEL-212, which is being developed for the ...
Selecta Biosciences' CEO referenced the "current market environment" when explaining the company's restructuring. (HAKINMHAN/iStock/Getty Images Plus) An analyst has reiterated that Selecta ...
WATERTOWN, Mass. and STOCKHOLM, Sweden, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB) and Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI), today announced topline ...
(RTTNews) - Selecta Biosciences Inc. (SELB) expects topline data from the Phase 3 DISSOLVE clinical program investigating SEL-212 in chronic refractory gout in the first-quarter of 2023. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results